Our study demonstrated that the dynamic change in TCRα and TCRβ diversity was correlated with the levels of tumor markers (CEA and CA19-9) and tumor size after medical treatment, which demonstrated the prognostic potential of the TCR repertoire for monitoring treatment responses in CRC. The gene discussed is CEACAM5; the disease is neoplasm.